A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer

Figure 4

The relative expression of HIF-1α and VEGF in four groups at day 14. A: Control group; B: UTMD group; C: TAE group; D: UTMD+TAE group.